Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Equity Average (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Equity Average for 3 consecutive years, with $165.8 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Equity Average rose 10.97% year-over-year to $165.8 million, compared with a TTM value of $165.8 million through Sep 2024, up 10.97%, and an annual FY2023 reading of $157.0 million, changed N/A over the prior year.
  • Equity Average was $165.8 million for Q3 2024 at Oramed Pharmaceuticals, down from $170.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $170.9 million in Q2 2024 and bottomed at $149.4 million in Q3 2023.
  • Average Equity Average over 3 years is $157.0 million, with a median of $154.3 million recorded in 2022.
  • The sharpest move saw Equity Average decreased 4.59% in 2023, then grew 13.65% in 2024.
  • Year by year, Equity Average stood at $152.2 million in 2022, then rose by 2.24% to $155.6 million in 2023, then increased by 6.61% to $165.8 million in 2024.
  • Business Quant data shows Equity Average for ORMP at $165.8 million in Q3 2024, $170.9 million in Q2 2024, and $164.3 million in Q1 2024.